Way back in the day when MannKind (NASDAQ: MNKD), who reported results last night, first started we noted that while Afrezza was a vast improvement over Exubera yet at the end of the day Afrezza was a multi-million-dollar product not a billion-dollar product. We knew Afrezza worked and there was a place for the drug in the treatment regimen. Yet we also knew the drug faced several formidable obstacles that would prevent the drug from becoming the blockbuster so many thought it would be.
Our biggest takeaway after seeing the results, reading the call transcript and reviewing . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.